<div id="readability-page-1"><div> By Elias Schisgall <pre></pre> Shares of Capricor Therapeutics fell after the company posted a wider-than-expected loss in the fourth quarter after not bringing in any revenue. Shares were down 8.6% to $30.54 in Friday afternoon trading. The stock has more than doubled in value in the past year. The biotechnology company on Thursday posted a quarterly loss of $30.2 million, or 62 cents a share, compared with a loss of $7.12 million, or 16 cents a share, a year earlier. Capricor did not post any revenue during the quarter, compared with $11.1 million a year prior. The company said its primary sources of revenue were $40 million in upfront and first-development milestone payments and $10 million in second-development milestone payments per the company's distribution agreement with Nippon Shinyaku. Those payments were recognized as of year-end 2024, it said. Analysts surveyed by FactSet were expecting $500,000 in revenue and a loss of 51 cents a share. The company said it is continuing to work toward approval for Deramiocel to treat Duchenne muscular dystrophy. A biologics license application for the treatment is under review by the Food and Drug Administration, and the company expects a response from the agency by Aug. 22. <pre></pre> Write to Elias Schisgall at elias.schisgall@wsj.com <pre></pre> (END) Dow Jones Newswires March 13, 2026 14:48 ET (18:48 GMT)Copyright (c) 2026 Dow Jones &amp; Company, Inc.</div></div>

SBIO

Capricor Therapeutics shares fell 8.6% to $30.54 after reporting a fourth-quarter loss of $30.2 million, significantly wider than analysts' expectations of a $500,000 revenue and a loss of 51 cents per share. The company did not generate any revenue during the quarter, down from $11.1 million a year earlier. Capricor is awaiting FDA approval for Deramiocel to treat Duchenne muscular dystrophy, with a response expected by August 22, 2026.

MorningStar

iShares Global Healthcare

VanEck Biotech ETF

ALPS Medical Breakthrough

Capricor Therap

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

Invesco Nasdaq Biotechnology ETF

VG Health

Direxion S&P Biotech Bull 3X

Health Care Select Sector SPDR

iShares US Pharma

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

iShares Biotechnology ETF

Capricor Therapeutics Falls on Wider-Than-Expected 4Q Loss